Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aktis Oncology, Inc. (AKTS) vs Monte Rosa Therapeutics, Inc. (GLUE)

Aktis Oncology, Inc. and Monte Rosa Therapeutics, Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Monte Rosa Therapeutics, Inc. are of similar size ($1.1B and $999.9M). Monte Rosa Therapeutics, Inc. has the higher net margin (−560.9% vs −782.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Monte Rosa Therapeutics, Inc. leads on 8 and Aktis Oncology, Inc. on 5.

Valuation

Metric AKTS GLUE Biotechnology median
P/E n/m n/m 7.88
P/S 112.39 41.58 11.47
P/B 2.24 2.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 58.83 19.96 10.73
Earnings yield (212.97%) (14.95%) (28.84%)
Free cash flow yield (12.84%) (2.69%) (23.03%)

Profitability

Metric AKTS GLUE Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (939.13%) (633.04%) 0.00%
Net margin (781.95%) (560.85%) 0.00%
Free cash flow margin (1,442.91%) (111.66%) 0.00%
Return on equity (34.45%) (42.66%) (57.72%)
Return on assets (27.09%) (30.67%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AKTS GLUE Biotechnology median
Revenue growth (TTM) — (83.86%) 5.64%
EPS growth (last fiscal year) (25.43%) 53.06% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AKTS GLUE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.33 10.58 4.73
Net debt to EBITDA 2.95 8.22 0.96

Dividend

Metric AKTS GLUE Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric AKTS GLUE Biotechnology median
Market cap 1.09b 999.87m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack